BioAtla and GATC Health have entered into a $40m special purpose vehicle (SPV) transaction to advance Ozuriftamab vedotin (Oz-V) into a Phase III trial for second-line and later (2L+) oropharyngeal squamous cell carcinoma (OPSCC). As part of transaction, BioAtla is set to receive an initial $5m from Inversagen AI, a newly established company focused on age-related disease research. The payment is intended for general operating and 2L+ OPSCC trial expenses. Inversagen AI was formed by GATC Health and In ...